Baudax Bio Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Malvern, Pennsylvania, USA
Total Funding:N/A
Industry:Pharma
Founded:2019
Lead Investor(s):N/A

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Baudax Bio's estimated annual revenue is currently $11.1M per year.(?)
  • Baudax Bio's estimated revenue per employee is $201,000

Employee Data

  • Baudax Bio has 55 Employees.(?)
  • Baudax Bio grew their employee count by 67% last year.
  • Baudax Bio currently has 1 job openings.

Baudax Bio is a specialty pharmaceutical company focused on developing and commercializing innovative products for patients in acute care settings. Baudax Bio was spun-out from Recro Pharma, Inc (REPH) in 2019 when Recro Pharma, Inc. separated its Acute Care Division from its Contract Drug Manufacturing Organization that together were ?Recro Pharma?. We are committed to bringing clinically meaningful therapeutic options to patients, health care providers, and payers, such as our lead product candidate, injectable meloxicam. We believe we can create value for patients and shareholders through our robust pipeline of product candidates. In addition, we continue to evaluate acquisition and licensing opportunities which align with our core acute care focus. Our lead product candidate is a proprietary IV injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials, including two pivotal efficacy trials, a large double-blind Phase III safety trial and other safety studies for the management of moderate to severe pain. Overall, the total New Drug Application (NDA) program included over 1,400 patients. We received two Complete Response Letters (CRL) for IV Meloxicam which we appealed to the first level and our appeal was granted. We are preparing a refiling of the NDA with a comprehensive response to the letter. Revised prescribing information will be included, along with the required update to safety summaries since the last filing. Our pipeline also includes other early-stage product candidates, including two novel neuromuscular blocker agents (NMBs) and a related proprietary chemical reversal agent, and Dex-IN, a proprietary intranasal formulation of dexmedetomidine, a selective alpha-2 adrenergic agonist that has demonstrated sedative, analgesic and anxiolytic properties.

keywords:N/A